Lipocine Inc. has initiated the BLOOM Phase 3 clinical trial to evaluate LPCN 1154, an oral brexanolone treatment for severe postpartum depression (PPD). The study plans to enroll about 120 participants, aiming to provide rapid symptom relief through a 48-hour at-home oral regimen. This trial follows a prior Phase 3 study that showed safety but did not meet primary endpoints, with new measures to improve data quality and reduce placebo effects. Lipocine expects to fund the study with existing resources and aims to support a future regulatory submission if results are positive.
Douglas Thompson, Chief Operating Officer of CAVA, purchased 6,500 shares of the company valued at $432,000. This insider buying could signal confidence in CAVA's future prospects. Investors often view such purchases as a positive sign, potentially i...
Cognizant has been recognized for the second consecutive year as one of America's Most Admired Workplaces by Newsweek and Plant-A Insights Group. This accolade reflects the company's success in attracting talent, engaging employees, and creating a po...
Webull now offers CME Group's E-nano S&P 500 and E-nano Nasdaq-100 futures, which are one-tenth the size of CME Micro E-mini futures. This allows retail investors to trade major U.S. equity indexes in smaller increments, reducing exposure and margin ...
First Citizens Bank's Middle Market Banking unit has extended $157 million in financing to Morningstar Properties to refinance its Blue Doors Storage Fund IV. This fund, managed by Morningstar's affiliate Blue Doors Capital Management, focuses on acq...
Sailfish Royalty Corp. announced a non-binding letter of intent with Mako Mining Corp. to purchase refined gold over 20 years, enabling Sailfish to pay a gold-linked dividend equivalent to one ounce of gold annually per 18,000 shares, plus a special ...
